Bioventus Inc.
NASDAQ:BVSMedical - Devices
+$0.18 today
- Market cap
- $727.20M
- Beta
- 0.67
- P/E (TTM)
- 20.6
- EPS (TTM)
- $0.42
Volume 0.70M
Average 0.56M
BVS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Bioventus Inc.NASDAQ: BVS
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue growth accelerates
Q1 FY2026 revenue of $132.09M rose 6.6% year over year, ahead of the +1.5% change in trailing-twelve-month revenue. Sequentially, it fell 16.3% from the prior quarter. Over 3 fiscal years it compounded at +3.5% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether revenue reaches the consensus estimate from 4 analysts of $592.31M (+4.3%) for the fiscal year ending Dec 2026, a step up from the -0.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $132.09M-16.3% QoQ
- Last fiscal yearDec 2025
- $568.09M-0.9% YoY
- LTMMar 2026
- $576.3M+1.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +6.6% | +5.3% | -1.4 pp |
| 1 year | -0.9% | +4.3% | +5.2 pp |
| 3-year CAGR | +3.5% | +6.0% | +2.4 pp |
| 5-year CAGR | +4.4% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 568.09M USD
- Year-over-year change
- -0.9%
- 4-year CAGR
- +7.2%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 568.09M | -0.9% |
| FY2024 | 2024-12-31 | 573.28M | +11.9% |
| FY2023 | 2023-12-31 | 512.35M | +0.0% |
| FY2022 | 2022-12-31 | 512.12M | +18.8% |
| FY2021 | 2021-12-31 | 430.9M | — |
Revenue vs competitors
How BVS compares with its peers on the latest reported figures
- BVS's LTM Mar 2026 revenue of $576.3M is the 4th highest of the 9 companies compared; the peer median is $451.49M.
- Its year-over-year change of +1.5% is the 7th highest of 9, against a peer median of +6.1%.
- Over three fiscal years its annual growth of +3.5% compares with a peer median of +11.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| FY2025 | $6.16B | +6.1% | +5.7% | |
| LTM Mar 2026 | $1.64B | +1.2% | +1.6% | |
| LTM Mar 2026 | $825.37M | +2.6% | +21.3% | |
| LTM Mar 2026 | $576.3M | +1.5% | +3.5% | |
| LTM Mar 2026 | $513.57M | +11.9% | +7.7% | |
| LTM Mar 2026 | $389.42M | +10.5% | +16.1% | |
| LTM Mar 2026 | $121.91M | -0.3% | +32.2% | |
| LTM Mar 2026 | $116.26M | +23.2% | -0.3% | |
| LTM Jun 2026 | $79.91M | +6.1% | +24.7% | |
| Peer median (excluding BVS) | $451.49M | +6.1% | +11.9% | |
Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 430.9M | 512.12M | 512.35M | 573.28M | 568.09M |
| Cost of Revenue | 128.19M | 181.04M | 184.15M | 185.05M | 185.66M |
| Gross Profit | 302.71M | 331.08M | 328.19M | 388.23M | 382.43M |
| Gross Margin | 70.3% | 64.6% | 64.1% | 67.7% | 67.3% |
| Research & Development | 19.04M | 23.85M | 13.45M | 13.64M | 12.11M |
| Selling, General & Admin | 254.25M | 332.13M | 303.88M | 327.09M | 311.77M |
| Operating Expenses | 290.65M | 498.31M | 409.92M | 400.21M | 323.88M |
| Depreciation & Amortization | 34.88M | 55.4M | 57.37M | 49.56M | 47.01M |
| EBITDA | 45.48M | (121.61M) | (23.07M) | 39.22M | 99.21M |
| EBITDA Margin | 10.6% | -23.7% | -4.5% | 6.8% | 17.5% |
| Operating Income | 12.06M | (167.23M) | (81.73M) | (11.98M) | 58.55M |
| Operating Margin | 2.8% | -32.7% | -16.0% | -2.1% | 10.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.11M | 12.02M | 40.68M | 38.79M | 26.49M |
| Other Income / Expenses | (2.57M) | (21.79M) | (39.39M) | (37.15M) | (32.84M) |
| Income Before Tax | 9.49M | (189.03M) | (121.11M) | (49.13M) | 25.71M |
| Pre-Tax Margin | 2.2% | -36.9% | -23.6% | -8.6% | 4.5% |
| Income Tax Expense | (1.97M) | (44.37M) | 85K | (5.29M) | (1.57M) |
| Net Income | 19.38M | (158.7M) | (156.23M) | (33.54M) | 22.73M |
| Net Margin | 4.5% | -31.0% | -30.5% | -5.9% | 4.0% |
| EPS (Basic) | (0.15) | (2.59) | (2.49) | (0.52) | 0.34 |
| EPS (Diluted) | (0.15) | (2.59) | (2.49) | (0.52) | 0.33 |
| Weighted Avg Shares | 45.47M | 61.39M | 62.65M | 65.36M | 66.62M |
| Weighted Avg Shares (Diluted) | 45.47M | 61.39M | 62.65M | 65.36M | 68.91M |
Bioventus Inc.
NASDAQ:BVS
Intrinsic Alpha fair value
Locked
Current Price
$10.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.